Welcome to LookChem.com Sign In|Join Free
  • or
1-(3-(4-nitrophenyl)propanoyl)azetidin-2-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1024602-82-1

Post Buying Request

1024602-82-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1024602-82-1 Usage

Class of compounds

Azetidinone

Pharmaceutical and biological activities

Various

2-one ring

A four-membered ring with a ketone group

4-nitrophenyl group

A phenyl group with a nitro group attached to the para position

Propanoyl side chain

A three-carbon chain with a carbonyl group at the end

Influence on bioactivity

The 4-nitrophenyl group can affect the compound's bioactivity

Potential pharmacological properties

The azetidinone ring contributes to the compound's potential pharmacological properties

Field of study

Medicinal chemistry

Further study and development

The compound has potential for further research and development in the field of medicinal chemistry

Check Digit Verification of cas no

The CAS Registry Mumber 1024602-82-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,4,6,0 and 2 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1024602-82:
(9*1)+(8*0)+(7*2)+(6*4)+(5*6)+(4*0)+(3*2)+(2*8)+(1*2)=101
101 % 10 = 1
So 1024602-82-1 is a valid CAS Registry Number.

1024602-82-1Relevant academic research and scientific papers

NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTTIBODY 38C2

-

Paragraph 0092; 00105, (2021/04/30)

The present invention provides modified catalytic antibody 38C2 with arylation of the reactive lysine residue (Lys99). The Lys99 residue is arylated with a heteroaryl methyl sulfonyl compound such as methylsulfone phenyl oxadi azole (MS- PODA). The invention also provides antibody conjugated agents (e.g., antibody drug conjugates) that contain an agent moiety that is site-specifically conjugated to 38C2 via a methyl sulfonyl compound. Further provided in the invention are methods of making the antibody conjugated agents and therapeutic applications of the antibody conjugated agents.

PROCESSES FOR PREPARING PEPTIDE CONJUGATES AND LINKERS

-

Paragraph 0173-0181, (2015/02/19)

The present invention provides a process for preparing a compound of Formula 5b, as well as intermediates thereof, and novel classes of compounds useful in process for preparing these and similar compounds.

Chromatography- and lyophilization-free synthesis of a peptide- linker conjugate

Magano, Javier,Bock, Brandon,Brennan, John,Farrand, Douglas,Lovdahl, Michael,Maloney, Mark T.,Nadkarni, Durgesh,Oliver, Wendy K.,Pozzo, Mark J.,Teixeira, John J.,Wang, Jian,Rizzo, John,Tumelty, David

, p. 142 - 151 (2014/05/20)

An optimized and scalable process to manufacture peptide-linker conjugate 1 is reported that avoids the chromatographic purification and lyophilization that are typically required for the isolation of this type of compound. An operationally simple protoco

Development of a long acting human growth hormone analog suitable for once a week dosing

Palanki, Moorthy S.S.,Bhat, Abhijit,Bolanos, Ben,Brunel, Florence,Del Rosario, Joselyn,Dettling, Danielle,Horn, Mark,Lappe, Rodney,Preston, Ryan,Sievers, Annette,Stankovic, Nebojsa,Woodnut, Gary,Chen, Gang

, p. 402 - 406 (2013/02/23)

Human growth hormone was conjugated to a carrier aldolase antibody, using a novel linker by connecting a disulphide bond in growth hormone to a lysine-94 amine located on the Fab arm of the antibody. The resulting CovX body showed reduced affinity towards human growth hormone receptor, reduced cell-based activity, but improved pharmacodynamic properties. We have demonstrated that this CovX-body, given once a week, showed comparable activity as growth hormone given daily in an in vivo hypophysectomized rat model.

Development of novel linkers to conjugate pharmacophores to a carrier antibody

Palanki, Moorthy S.S.,Bhat, Abhijit,Lappe, Rodney W.,Liu, Bin,Oates, Bryan,Rizzo, John,Stankovic, Nebojsa,Bradshaw, Curt

, p. 4249 - 4253 (2012/07/17)

We have developed modified maleimide novel linkers with improved chemical stability that could potentially be used in conjugating various pharmacophores such as oligo nucleotides, peptides, and proteins to antibodies to afford novel biologics with well-de

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1024602-82-1